Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 12/20 | 0.50 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.47 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.47 |
| ▸ | PLK1 | P53350 | 2/20 | 0.47 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.47 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.47 |
| ▸ | PAK4 | O96013 | 1/20 | 0.47 |
| ▸ | AKT1 | P31749 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | CRHBP | P24387 | 1/20 | 0.45 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 2/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13109674 | 0.87 | HSP90AB1 (0.52) | APPHSP90AB1CSNK2A2PLK1CSNK2B | |
| SCHEMBL13109542 | 0.83 | CSNK2A1 (0.58) | HSP90AB1CSNK2A2PLK1CSNK2BCSNK2A1 | |
| SCHEMBL13109563 | 0.78 | ALDH1A1 (0.46) | HSP90AB1CSNK2A2PLK1CSNK2BCSNK2A1 | |
| SCHEMBL13125847 | 0.75 | CSNK2A2 (0.55) | HSP90AB1CSNK2A2PLK1CSNK2BCSNK2A1 | |
| SCHEMBL5254463 | 0.75 | ABL1 (0.53) | HSP90AB1CSNK2A2PLK1CSNK2BCSNK2A1 | |
| SCHEMBL13109574 | 0.75 | MAPT (0.51) | HSP90AB1CSNK2A2PLK1CSNK2BCSNK2A1 | |
| SCHEMBL760559 | 0.74 | HSP90AB1 (0.50) | HSP90AB1CSNK2A2PLK1CSNK2BCSNK2A1 | |
| SCHEMBL14611037 | 0.72 | CSNK2A2 (0.46) | HSP90AB1CSNK2A2PLK1CSNK2BCSNK2A1 | |
| SCHEMBL8185671 | 0.72 | CYP1A2 (0.53) | KDM4EALDH1A1HPGDCRHBPCRHR2 | |
| SCHEMBL13109576 | 0.72 | HSP90AB1 (0.46) | HSP90AB1KDM4EALDH1A1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1675861-B1 | PYRIMIDOTHIOPHENE COMPOUNDS | VERNALIS R&D LTD (GB) | 2015-12-23 | — | — | EP | disclosed |
| EP-1675861-B1 | PYRIMIDOTHIOPHENE COMPOUNDS | VERNALIS R&D LTD (GB) | 2015-12-23 | — | — | EP | disclosed |
| US-8642594-B2 | Substituted thieno[2,3-d]pyrimidines as HSP90 inhibitors | VERNALIS (R&D) LIMITED (GB) | 2014-02-04 | — | — | US | disclosed |
| US-8642594-B2 | Substituted thieno[2,3-d]pyrimidines as HSP90 inhibitors | VERNALIS (R&D) LIMITED (GB) | 2014-02-04 | — | — | US | disclosed |
| US-8642594-B2 | Substituted thieno[2,3-d]pyrimidines as HSP90 inhibitors | VERNALIS (R&D) LIMITED (GB) | 2014-02-04 | — | — | US | disclosed |
| US-7820658-B2 | Substituted thieno[2,3-d]pyrimidines as HSP90 inhibitors | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2010-10-26 | — | — | US | disclosed |
| US-7820658-B2 | Substituted thieno[2,3-d]pyrimidines as HSP90 inhibitors | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2010-10-26 | — | — | US | disclosed |
| US-7820658-B2 | Substituted thieno[2,3-d]pyrimidines as HSP90 inhibitors | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2010-10-26 | — | — | US | disclosed |
| US-20100120767-A1 | Pyrimidothiophene Compounds | Barril-Alonso, Xavier (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20100120767-A1 | Pyrimidothiophene Compounds | Barril-Alonso, Xavier (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20100120767-A1 | Pyrimidothiophene Compounds | Barril-Alonso, Xavier (GB) | 2010-05-13 | — | — | US | disclosed |
| CN-100455586-C | Pyrimidothiophene compounds | VERNALIS CAMBRIDGE LTD (GB) | 2009-01-28 | — | — | CN | disclosed |
| US-20070043044-A1 | Pyrimidothiophene compounds | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2007-02-22 | — | — | US | disclosed |
| US-20070043044-A1 | Pyrimidothiophene compounds | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2007-02-22 | — | — | US | disclosed |
| US-20070043044-A1 | Pyrimidothiophene compounds | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2007-02-22 | — | — | US | disclosed |
| CN-1842532-A | Pyrimidothiophene compounds | VERNALIS CAMBRIDGE LTD (GB) | 2006-10-04 | — | — | CN | disclosed |
| EP-1675861-A1 | PYRIMIDOTHIOPHENE COMPOUNDS | Vernalis (Cambridge) Limited (GB) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005021552-A1 | PYRIMIDOTHIOPHENE COMPOUNDS | VERNALIS (CAMBRIDGE) LTD (GB) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120767-A1 | Pyrimidothiophene Compounds | ALK, HSP90AA1, HSP90AB1 | APP 3320/4885HSP90AB1 3/4885CSNK2A2 745/4885 |
| US-20070043044-A1 | Pyrimidothiophene compounds | ALK, HSP90AA1, HSP90AB1 | APP 2992/4885HSP90AB1 3/4885CSNK2A2 891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.